EMEA leaves it late and APAC remains quiet; valuations low Q1 2019 started off in style, with Bristol-Myers Squibb announcing a $96.8bn offer for US-based Celgene Corp just three days into the new year. Since then global M&A volume has been somewhat underwhelming. However, a late volume resurgence during the last two weeks of the … Continue reading M&A Highlights: Q1 2019